The slip
PARKINSON RECEIPTno. 10849
26 Oct 2026, 12:45 UTCastrocytes, braak
predictionRAPGEF3 in astrocytes tracks Braak Lewy-body stage
registeredcb419839bf7ecdca
discovery+0.07 p=0.849 n=9
replication+0.52 p=0.153 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.07, p 0.849)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECTc5a39e6a76e8935130c7aeb0…
follows ca6502685dbe…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 10849: RAPGEF3 in astrocytes, braak
- power
- full sample +0.21 (p 0.398, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.25 (p 0.319, n 18). does not hold up.
- composition
- astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.19 (p 0.455, n 18). could be the mix.
- skeptic
- leave-one-out range +0.12 to +0.37, sign flips 0; without severely affected donors +0.21 (p 0.398, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.67 (p 0.0022, n 18) vs +0.21 in astrocytes. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RAPGEF3 in astrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up RAPGEF3 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.15 p 0.594 (needs p < 2.0e-4)